The ?4 subunit of the ?6?4 integrin, which forms hemidesmosomes in quiescent normal cells, becomes phosphorylated in breast tumor cells that overexpress HER2 or EGFR. This phosphorylation converts the cytoplasmic domain of the integrin into a signaling scaffold that drives cell invasion, proliferation and survival. HER2 and EGFR are expressed in HER2+/ER- breast cancer, and EGFR is overexpressed in the triple- negative (HER2-,ER-,PR-) subtype. Both cancers are highly aggressive and resist treatments currently available in the clinic. Because these cancer types often overexpress the ?6?4 integrin as well, we have now examined their dependence on signaling from these receptor complexes. We have discovered that these signaling mechanisms are essential for the growth and survival on the cancer cells, and that their signaling requires the assembly of the integrin and HER2 or EGFR with syndecans, another family of matrix receptors. Indeed, syndecan-1 appears necessary for signaling by HER2??6?4, and syndecan-4 appears to be required by EGFR??6?4. Our goal is to define the molecular details of syndecan assembly with these signaling complexes, develop mutants and blocking peptides that disrupt the organizing function of these two syndecans, and test the mutants and peptides in tumor growth, angiogenesis and the activity of cancer stem cells in animal models of HER2+ and TN breast cancer. The outcome of this work will provide potential insight into the development of new therapeutics to target HER2+ and TN breast cancer.
About 12% of the women in the United States can expect to get breast cancer during their lifetimes. Although death rates have been declining, largely due to improved hormone therapies, many patients do not response to these treatments (especially estrogen receptor negative (the HER2+/ER- and triple-negative subtypes) and have limited treatment options. We propose to study two new mechanisms involving the matrix receptors syndecan-1 and syndecan-4 that appear to control the survival of these tumors, and likely regulate the cancer stem cells and angiogenesis upon which they depend, and to develop potential new therapeutics to target these mechanisms.
|Beauvais, DeannaLee M; Jung, Oisun; Yang, Yang et al. (2016) Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth. Cancer Res 76:4981-93|
|Tan, Xiaojun; Lambert, Paul F; Rapraeger, Alan C et al. (2016) Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. Trends Cell Biol 26:352-66|
|Jung, O; Trapp-Stamborski, V; Purushothaman, A et al. (2016) Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins. Oncogenesis 5:e202|
|Wang, Haiyao; Jin, Haining; Rapraeger, Alan C (2015) Syndecan-1 and Syndecan-4 Capture Epidermal Growth Factor Receptor Family Members and the Î±3Î²1 Integrin Via Binding Sites in Their Ectodomains: NOVEL SYNSTATINS PREVENT KINASE CAPTURE AND INHIBIT Î±6Î²4-INTEGRIN-DEPENDENT EPITHELIAL CELL MOTILITY. J Biol Chem 290:26103-13|
|Wang, Haiyao; Jin, Haining; Beauvais, DeannaLee M et al. (2014) Cytoplasmic domain interactions of syndecan-1 and syndecan-4 with Î±6Î²4 integrin mediate human epidermal growth factor receptor (HER1 and HER2)-dependent motility and survival. J Biol Chem 289:30318-32|